A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669 Meeting Abstract


Authors: Cohen, E. E. W.; Rischin, D.; Pfister, D. G.; Vermorken, J. B.; Zhao, Y.; Gowda, H.; Ge, J. Y.; Jin, F.; Harrington, K. J.
Abstract Title: A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 344s
Language: English
ACCESSION: WOS:000442916007693
DOI: 10.1200/JCO.2018.36.15_suppl.TPS6090
PROVIDER: wos
Notes: Meeting Abstract: TPS6090 -- Source: Wos
Altmetric Score
MSK Authors
  1. David G Pfister
    247 Pfister